DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

with the injection taking only a few seconds. Laser therapy involves applying small laser pulses to seal leaking blood vessels and reduce macular swelling. Laser therapy can help stabilize and ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

Blindness or vision loss is a growing concern among older adults, and one of the leading causes is a condition known as ...

A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...

The drugs are administered by injection directly into the gel-filled vitreous chamber of the eye that separates the lens and the retina. These intravitreal injections can work very well.

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.